Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 15/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4867237 | 0.87 | AOC3 (0.73) | AOC3ALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL14045018 | 0.83 | AOC3 (0.55) | AOC3ALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL4874138 | 0.77 | AOC3 (0.57) | AOC3ALDH1A1MAPTGAAPIK3CG | |
| SCHEMBL27646792 | 0.76 | AOC3 (0.56) | AOC3ALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL27626538 | 0.75 | AOC3 (0.56) | AOC3ALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL4877874 | 0.75 | AOC3 (0.77) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4874385 | 0.75 | AOC3 (0.77) | AOC3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4867104 | 0.74 | AOC3 (0.75) | AOC3ALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL27626576 | 0.73 | AOC3 (0.54) | AOC3ALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL14019534 | 0.73 | AOC3 (0.55) | AOC3ALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | AOC3 202/4885ALDH1A1 927/4885MAPT 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.